|
US5358941A
(en)
*
|
1992-12-02 |
1994-10-25 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids with lactose
|
|
WO1995003009A1
(en)
|
1993-07-22 |
1995-02-02 |
Oculex Pharmaceuticals, Inc. |
Method of treatment of macular degeneration
|
|
WO1995003807A1
(en)
|
1993-07-27 |
1995-02-09 |
The University Of Sydney |
Treatment of age-related macular degeneration
|
|
EP0716597A1
(en)
|
1993-08-30 |
1996-06-19 |
Warner-Lambert Company |
Tablet coating based on a melt-spun mixture of a saccharide and apolymer
|
|
IT1274549B
(it)
|
1995-05-23 |
1997-07-17 |
Indena Spa |
Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
|
|
US5800819A
(en)
|
1996-01-25 |
1998-09-01 |
National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology |
Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
DE69740140D1
(de)
|
1996-07-24 |
2011-04-14 |
Celgene Corp |
Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
US6015803A
(en)
|
1998-05-04 |
2000-01-18 |
Wirostko; Emil |
Antibiotic treatment of age-related macular degeneration
|
|
US6225348B1
(en)
|
1998-08-20 |
2001-05-01 |
Alfred W. Paulsen |
Method of treating macular degeneration with a prostaglandin derivative
|
|
US6001368A
(en)
|
1998-09-03 |
1999-12-14 |
Protein Technologies International, Inc. |
Method for inhibiting or reducing the risk of macular degeneration
|
|
US6020358A
(en)
|
1998-10-30 |
2000-02-01 |
Celgene Corporation |
Substituted phenethylsulfones and method of reducing TNFα levels
|
|
US6448323B1
(en)
*
|
1999-07-09 |
2002-09-10 |
Bpsi Holdings, Inc. |
Film coatings and film coating compositions based on polyvinyl alcohol
|
|
SK7292002A3
(en)
*
|
1999-10-29 |
2002-12-03 |
Smithkline Beecham Corp |
Pharmaceutical composition with controlled release for increasing the dose or system exposure of a medicament inhibiting pde4
|
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
|
US20040190609A1
(en)
|
2001-11-09 |
2004-09-30 |
Yasuhiko Watanabe |
Moving picture coding method and apparatus
|
|
MY140561A
(en)
*
|
2002-02-20 |
2009-12-31 |
Nycomed Gmbh |
Dosage form containing pde 4 inhibitor as active ingredient
|
|
AU2003222034A1
(en)
|
2002-03-20 |
2003-10-08 |
Celgene Corporation |
(-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US20050203142A1
(en)
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
US20040091455A1
(en)
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US20050100529A1
(en)
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
|
BRPI0417186A
(pt)
|
2003-12-02 |
2007-03-06 |
Celgene Corp |
método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
|
|
US20050143344A1
(en)
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
|
AU2005226649B2
(en)
|
2004-03-22 |
2010-04-29 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
|
US20050222209A1
(en)
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
|
BRPI0510110A
(pt)
|
2004-04-23 |
2007-09-25 |
Celgene Corp |
método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
|
|
WO2006053160A2
(en)
|
2004-11-12 |
2006-05-18 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
|
|
CN101102771A
(zh)
|
2004-11-23 |
2008-01-09 |
细胞基因公司 |
用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物
|
|
AU2005311888A1
(en)
|
2004-12-01 |
2006-06-08 |
Celgene Corporation |
Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
|
|
JP2008530145A
(ja)
*
|
2005-02-15 |
2008-08-07 |
ワイス |
経口投与可能なｃｃｉ−７７９製剤
|
|
EP1858514B1
(en)
*
|
2005-03-17 |
2014-11-26 |
Synthon B.V. |
Pharmaceutical tablets of crystalline type ii aripiprazole
|
|
WO2006111980A2
(en)
|
2005-04-20 |
2006-10-26 |
Ideal Cures Pvt. Ltd. |
Pva based film coating and film coating compositions
|
|
PL1928492T3
(pl)
|
2005-09-01 |
2011-09-30 |
Celgene Corp |
Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby
|
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
|
US8927546B2
(en)
*
|
2006-02-28 |
2015-01-06 |
Dart Neuroscience (Cayman) Ltd. |
Therapeutic piperazines
|
|
DK2276483T3
(da)
*
|
2008-03-27 |
2014-06-10 |
Celgene Corp |
Faste former, omfattende (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion, sammensætninger deraf og anvendelser deraf
|
|
DE102008047910A1
(de)
|
2008-09-19 |
2010-03-25 |
Molkerei Meggle Wasserburg Gmbh & Co. Kg |
Tablettierhilfsstoff auf Laktose- und Cellulosebasis
|
|
EP2196465A1
(en)
|
2008-12-15 |
2010-06-16 |
Almirall, S.A. |
(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
|
|
MY160002A
(en)
|
2009-02-10 |
2017-02-15 |
Celgene Corp |
Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
|
|
CA3002948C
(en)
*
|
2009-11-13 |
2020-10-27 |
Astrazeneca Uk Limited |
Immediate release tablet formulations
|
|
MX2012004741A
(es)
|
2009-11-19 |
2012-05-22 |
Celgene Corp |
Apremilast para el tratamiento de sarcoidosis.
|
|
MX354210B
(es)
*
|
2010-12-16 |
2018-02-16 |
Celgene Corp |
Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
|
|
AU2012362562B2
(en)
|
2011-12-27 |
2017-11-02 |
Amgen (Europe) GmbH |
Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
|